177 related articles for article (PubMed ID: 36072540)
41. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
[TBL] [Abstract][Full Text] [Related]
42. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
[TBL] [Abstract][Full Text] [Related]
43. Genetic Polymorphism of CYP2C19 in Pakistani Population.
Riaz S; Muhammad Din S; Usman Tareen M; Tariq F; Latif Y; Siddiqi S; Sultan A; Mansoor A
Iran J Pharm Res; 2019; 18(2):1097-1102. PubMed ID: 31531091
[TBL] [Abstract][Full Text] [Related]
44. Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?
Miller MA; Lee YM
Curr Fungal Infect Rep; 2020 Mar; 14(1):63-75. PubMed ID: 32256938
[TBL] [Abstract][Full Text] [Related]
45. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
Calcagno A; Baietto L; Pagani N; Simiele M; Audagnotto S; D'Avolio A; De Rosa FG; Di Perri G; Bonora S
Pharmacogenomics; 2014 Jul; 15(10):1281-6. PubMed ID: 25155930
[TBL] [Abstract][Full Text] [Related]
46. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.
Zeng G; Wang L; Shi L; Li H; Zhu M; Luo J; Zhang Z
Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875
[TBL] [Abstract][Full Text] [Related]
47. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
[TBL] [Abstract][Full Text] [Related]
48. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
49. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
[TBL] [Abstract][Full Text] [Related]
50. Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center.
Lindsay J; Krantz EM; Morris J; Sweet A; Tverdek F; Joshi A; Yeh R; Hill JA; Greenwood M; Chen SC; Kong DCM; Slavin M; Pergam SA; Liu C
Transplant Cell Ther; 2022 Aug; 28(8):511.e1-511.e10. PubMed ID: 35623614
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
[TBL] [Abstract][Full Text] [Related]
52. Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status.
Lan H; Ying T; Xi-Hua S; Yi L
Cell Transplant; 2019 Aug; 28(8):1039-1044. PubMed ID: 31134829
[TBL] [Abstract][Full Text] [Related]
53. Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response.
Liu XL; Jia QJ; Wang LN; Liu ZM; Liu H; Duan XC; Lyu XM
Med Sci Monit; 2016 Jan; 22():310-5. PubMed ID: 26822491
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic Drug Monitoring of Voriconazole in Patients with End-Stage Liver Disease.
Wu Z; Jiang M; Yan M; Li G; Zeng Z; Zhang X; Li N; Jiang Y; Gong G; Zhang M
Ther Drug Monit; 2024 Feb; 46(1):89-94. PubMed ID: 38192036
[TBL] [Abstract][Full Text] [Related]
55. Differences in the Proportion of CYP2C19 Loss-of-Function Between Cerebral Infarction and Coronary Artery Disease Patients.
Shi Y; Yang Y; Feng M; Ling W; Wei T; Cao Y; Zhong R; Wu H
Int J Gen Med; 2023; 16():3473-3481. PubMed ID: 37601806
[TBL] [Abstract][Full Text] [Related]
56. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.
Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM
Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y
Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277
[TBL] [Abstract][Full Text] [Related]
58. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.
Kim H; Kim Y; Koh YS; Lee HK; Chae H; Jekarl DW; Lee JM; Shin WS; Kim TH
Platelets; 2015; 26(2):148-53. PubMed ID: 24617511
[TBL] [Abstract][Full Text] [Related]
60. [Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013-2014)].
Valenzuela R; Torres JP; Salas C; Gajardo I; Palma J; Catalán P; Santolaya ME; Morales J
Rev Chilena Infectol; 2017 Feb; 34(1):14-18. PubMed ID: 28394976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
